Antenatal and intrapartum nucleic acid amplification test use for group B Streptococcus screening—United States, 2016

Publication date: Available online 11 December 2018

Source: Diagnostic Microbiology and Infectious Disease

Author(s): Katherine Fay, Olivia Almendares, Barbara Robinson-Dunn, Stephanie Schrag

Abstract

Perinatal group B Streptococcal (GBS) disease prevention guidelines in 2010 allowed for processing of screening specimens by nucleic acid amplification tests (NAATs); however the extent of NAAT use is unknown. A 2016 laboratory survey sent to ten surveillance sites found that 18.7% of responding laboratories offered NAAT for GBS screening (antenatal only: 7.3%; intrapartum only: 4.1%; both: 3.4%).

from ! ORL Sfakianakis via paythelady.61 on Inoreader https://ift.tt/2Ed3BXf
via IFTTT